DAWN Day One Biopharmaceuticals, Inc.

XNAS 21.53 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DAWN $21.53 —
Key stats
$21.53
52-Week Range
$7.90 – $21.53
YTD
+143.28%
Straddle Price
$9.35
P/C Vol Ratio (May 15 expiry)
0.04
Market Cap
$2.2B
Open
$21.50
Day Range
$21.49 – $21.53
Volume
2,984,744
Prev Close
$21.49
Fair Value
-16.4% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.00%
Beta vs SPY1.00
Cost of Equity (CAPM)9.50% (VRP-adj)
WACC9.50%
Volatility Risk Premium+436.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-24.3%
Book / Price19.9%
Gross Margin (TTM)89.1%
FCF Margin (TTM)-65.8%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$18.01 (Market Anchor value)
SMA 20 / Bollinger Mid$21.45
Bollinger Width / SMA203.1% (drives anchor stability)
Net Debt$-0.2B
Market Cap$2B
Blended Fair Value
$18.01
Deviation
-16.4%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $18.01 100% stability 100% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-01 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$2.2B
Employees
178
List Date
2021-05-27
CIK
0001845337
Last Earnings
Jan 12 after close · −6.5% vs ±7.7% expected
Headquarters
Brisbane, CA
Homepage
https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Insufficient price history — listed 2002 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $21.45
SMA 50: $18.01
SMA 200: $10.65
Current: $21.53
EMA 12: $21.43
EMA 26: $20.64
MACD: 0.7882 | Signal: -0.2787
BULLISH
ADX (14): 65.43
STRONG TREND
+DI: 53.04
−DI: 9.71

Momentum Oscillators

RSI (14): 80.32
OVERBOUGHT
Stoch %K: 92.13
Stoch %D: 84.48
Williams %R: 0.00

Volume & Volatility

BB Upper: $21.52
BB Lower: $21.38
OVERBOUGHT
OBV: 115,762,561
Vol SMA 20: 1,612,102
Vol ROC: 96.02%
ATR: $0.17
True Range: $0.04
HV 20: 1.5%
HV 30: 2.5%
HV 60: 122.3%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-04-24T00:00:00 – 2026-04-22T00:00:00
AI Analysis

LLM Stock Analysis Report - DAWN

Executive Summary

Executive Assessment: BEARISH (Confidence Level: 7/10)

Key Drivers:

  • Technical signals indicate an overbought condition, with RSI >70 and Stochastic %K >92
  • MACD signal line crossover suggests momentum is waning
  • Options metrics show a low IV rank, indicating historically low volatility

Primary Risks:

  • Overbought conditions may lead to price corrections or consolidations
  • Negative beta (-0.01) suggests the stock moves opposite to market, increasing risk

Investment Thesis: DAWN's recent strong performance is likely to be corrected in the near term due to overbought technical indicators and negative market sentiment. However, if these indicators are not confirmed by fundamental changes, a potential reversal or consolidation may occur.

Recent News Sentiment Impact: The recent news headlines have been largely positive, with three out of six articles highlighting the company's financial performance, business achievements, and product launches. This sentiment has contributed to the stock's upward momentum but may also indicate a short-term correction is necessary.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Downtrend
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Uptrend

Support/Resistance Levels:

  • Resistance: $21.53 (current price)
  • Support: $20.64 (EMA 26)

Momentum Signals: RSI interpretation: Overbought (>70) with a potential sell signal MACD signal line crossover: Bearish momentum signal Bollinger Bands position: Squeeze and potential breakout

Volume Analysis: Volume trends indicate institutional interest, but the volume rate of change suggests waning enthusiasm.

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines highlight the company's financial performance, business achievements, and product launches. While this sentiment has contributed to the stock's upward momentum, it may also indicate a short-term correction is necessary.

Sentiment Assessment: POSITIVE ( Aggregate sentiment from last 10 articles)

Catalyst Identification: Upcoming events and announcements that could impact the stock price include earnings releases, FDA approvals, and product launches. However, no specific catalysts are identified in the given data.

Market Narrative: The recent news headlines align with the technical signals, indicating a potential correction or consolidation is necessary to rebalance the market.

Risk & Volatility Assessment

Risk Assessment: HIGH RISK (Confidence Level: 8/10)

Beta Interpretation: Negative beta (-0.01) suggests the stock moves opposite to market, increasing risk

Volatility Regime: Current volatility levels are relatively low compared to historical data.

Options Market Signals: IV rank is low (4.7%), indicating historically low volatility Put/call ratios and unusual activity suggest a bullish sentiment

Downside Protection: Support levels include EMA 26 ($20.64) and potential long-term support at SMA 200 ($10.65)

Market Context & Positioning

Market Performance: DAWN has outperformed the market, with a beta of -0.01 indicating it moves opposite to the broader market.

Institutional Activity: Volume patterns suggest institutional interest, but the volume rate of change indicates waning enthusiasm.

Correlation Analysis: The stock's correlation with the market is negative (-0.00), suggesting it may move independently.

Relative Valuation: DAWN's relative valuation suggests it is positioned within a trading range, potentially indicating a correction or consolidation.

Key Levels & Action Items

Critical Price Levels:

  • Support: $20.64 (EMA 26)
  • Resistance: $21.53 (current price)

Breakout/Breakdown Levels:

  • Breakout above $22.00 could indicate a continuation of the uptrend
  • Breakdown below $19.50 could signal a more significant correction

Time-Sensitive Catalysts: No specific catalysts are identified in the given data.

Risk Management: Stop-loss levels and position sizing considerations should be adjusted based on the analysis, with potential stop-loss levels at $20.64 (EMA 26) and $21.00 (short-term support).

Generated
Earnings History
13 of 14 under expected move
Avg Expected Move
18.05%
Avg Actual Move
7.26%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2022-08-04 After-Close 19.32% 15.60% 0.81x Within
2023-03-06 After-Close 5.17% 7.46% 1.44x Exceeded
2023-05-01 After-Close 12.09% 3.39% 0.28x Within
2023-08-07 After-Close 12.13% 5.66% 0.47x Within
2023-11-06 After-Close 11.32% 1.39% 0.12x Within
2024-02-26 After-Close 13.29% 11.05% 0.83x Within
2024-05-06 After-Close 17.05% 2.89% 0.17x Within
2024-07-30 After-Close 13.66% 5.79% 0.42x Within
2024-10-30 After-Close 11.06% 1.73% 0.16x Within
2025-02-25 Pre-Market 21.96% 2.96% 0.13x Within
2025-05-06 After-Close 31.12% 9.87% 0.32x Within
2025-08-05 Pre-Market 31.92% 2.15% 0.07x Within
2025-11-04 After-Close 44.86% 25.21% 0.56x Within
2026-01-12 After-Close 7.72% 6.53% 0.85x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DAWN Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $9.35
7-DTE Move: $9.35
Days to Exp: 23 (2026-05-15)

Options Flow · May 15 expiry

Call Volume: 24
Put Volume: 1
P/C Volume: 0.042
BULLISH
Call OI: 414
Put OI: 405
P/C OI: 0.978
Total OI: 819

ATM Options Pricing

ATM Call: $7.50
ATM Put: $1.85
Call %: 34.8%
Put %: 8.6%

Chain Summary

Chain Volume: 1,542
Chain OI: 22,804
Last Updated: 4/22/2026

DAWN Implied Volatility

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much DAWN actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
1%
vs own history
GEX tilt
-0.38
OI-weighted, today
Vanna tilt
+0.98
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.98: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 10 ATM contracts, 9k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
as of Apr 22 · No data
30 DTE / 10d put —
— pts EXTREME
as of Apr 22 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$9.35Apr 22
Beta Analysis
Insufficient price history — listed 2002 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

DAWN Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

DAWN Insider Trading (Form 4)

Latest: 2026-04-23
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-04-23 William Grossman Director Disp (D) −136,495 opt — EDGAR
2026-04-23 Habib J Dable Director Disp (D) −136,495 opt — EDGAR
2026-04-23 Lauren Merendino Chief Commercial Officer Disp (D) −60,157 — EDGAR
2026-04-23 Michael Vasconcelles Head of Research and Dev. Disp (D) −4,397 — EDGAR
2026-04-23 J. Scott Garland Director Disp (D) −184,107 opt — EDGAR
2026-04-23 Garry A Nicholson Director Disp (D) −141,235 opt — EDGAR
2026-04-23 Adam Dubow Gen Counsel & Secretary Disp (D) −72,694 — EDGAR
2026-04-23 Charles N York II COO and CFO Disp (D) −312,025 — EDGAR
2026-04-23 Natalie C. Holles Director Disp (D) −57,310 — EDGAR
2026-04-23 Jeremy Bender CHIEF EXECUTIVE OFFICER Disp (D) −1,799,031 — EDGAR
2026-04-23 John A. Josey Director Disp (D) −72,292 — EDGAR
2026-04-23 Saira Ramasastry Director Disp (D) −40,485 — EDGAR
2026-02-18 Charles N York II COO and CFO Mixed
Exer +23,375 · Sell −6,065
+17,310 $11.60 -$70.4K EDGAR
2026-02-18 Michael Vasconcelles Head of Research and Dev. Mixed
Exer +7,125 · Sell −2,728
+4,397 $11.60 -$31.6K EDGAR
2026-02-18 Adam Dubow Gen Counsel & Secretary Mixed
Sell −6,395 · Exer +16,463
+10,068 $11.60 -$74.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DAWN Insider Holdings

1 insider · @ $21.53
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Samuel C. Blackman HEAD OF R&D 2,034,015 $43.79M -$6.62M 38 2024-12-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DAWN Board & Officers

As of SEC filings through Apr 27, 2026
Changes in the last 10 years (58)
Apr 27, 2026AI Day1 LLC reported in an SEC filing no longer being a 10% owner
Apr 23, 2026William Grossman reported in an SEC filing no longer being a director
Apr 23, 2026Saira Ramasastry reported in an SEC filing no longer being a director
Apr 23, 2026Natalie C. Holles reported in an SEC filing no longer being a director
Apr 23, 2026Michael Vasconcelles reported in an SEC filing no longer being Head of Research and Dev.
Apr 23, 2026Lauren Merendino reported in an SEC filing no longer being Chief Commercial Officer
Apr 23, 2026John A. Josey reported in an SEC filing no longer being a director
Apr 23, 2026Jeremy Bender reported in an SEC filing no longer being a director
Apr 23, 2026Jeremy Bender reported in an SEC filing no longer being Chief Executive Officer
Apr 23, 2026J. Scott Garland reported in an SEC filing no longer being a director
Apr 23, 2026Habib J Dable reported in an SEC filing no longer being a director
Apr 23, 2026Garry A Nicholson reported in an SEC filing no longer being a director
Apr 23, 2026Charles N York II reported in an SEC filing no longer being COO and CFO
Apr 23, 2026Adam Dubow reported in an SEC filing no longer being Gen Counsel & Secretary
Aug 19, 2025Charles N York II listed as COO and CFO (previously COO, CFO and Secretary) in SEC filings
Aug 19, 2025Adam Dubow listed as Gen Counsel & Secretary (previously General Counsel) in SEC filings
Jun 16, 2025Michael Vasconcelles became Head of Research and Dev.
Feb 26, 2025Lauren Merendino became Chief Commercial Officer
Nov 20, 2024The company announced the departure of Samuel C. Blackman as Head of R&D in an SEC filing
Feb 28, 2024Samuel C. Blackman listed as Head of R&D (previously Head of Research and Developme) in SEC filings
Not reported recently (12)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

DAWN Proposed Insider Sales (Form 144)

Latest: 2026-02-17
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-02-17 JEREMY BENDER Officer, Director 15,459 $179.3K 2026-02-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-02-17 CHARLES YORK Officer 6,065 $70.4K 2026-02-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-02-17 LAUREN MERENDINO Officer 5,814 $67.4K 2026-02-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-02-17 ADAM DUBOW Officer 6,395 $74.2K 2026-02-17 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-17 CHARLES YORK Officer 4,062 $36.2K 2025-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-17 LAUREN MERENDINO Officer 3,726 $33.2K 2025-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-17 ADAM DUBOW Officer 4,319 $38.5K 2025-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-17 JEREMY BENDER Officer, Director 15,894 $141.7K 2025-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2025-08-18 JEREMY BENDER Officer, Director 16,058 $108.7K 2025-08-18 Morgan Stanley Smith Barney LLC … — EDGAR
2025-05-16 CHARLES YORK Officer 4,282 $26.8K 2025-05-16 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.04
TTM Revenue
$158.18M
TTM Net Income
$-107.32M
TTM Op. Cash Flow
$-103.76M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '252025-12-31$53.72M$-21.28M$-0.21$-14.15M
Q3 '252025-09-30$39.80M$-19.73M$-0.19$-5.80M
Q2 '252025-06-30$33.91M$-30.32M$-0.29$-24.81M
Q1 '252025-03-31$30.76M$-36.00M$-0.35$-59.00M
Q4 '242024-12-31$29.21M$-65.71M$-0.69$-30.01M
Q3 '242024-09-30$93.76M$37.04M$0.38$50.75M
Q2 '242024-06-30$8.19M$-4.41M$-0.05$-49.13M
Q1 '242024-03-31—$-62.41M$-0.72$-49.73M
Q4 '232023-12-31—$-54.51M$-0.64$-41.37M
Q3 '232023-09-30—$-46.15M$-0.54$-37.06M
Q2 '232023-06-30—$-45.86M$-0.61$-42.43M
Q1 '232023-03-31—$-42.39M$-0.59$-25.98M
Q4 2025 • period ending 2025-12-31 • filed 2026-02-24
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.03
P/S
14.03
EV/EBITDA
—
EV/Sales
12.79
ROE
-24.3%
ROA
-21.1%
Div Yield
0.00%
FCF Yield
-4.67%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.22B
as of 2026-04-22

DAWN vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 43.9 +45.5% +25.2% 37
JNJ Johnson & Johnson $656.5B 40.4 +7.8% +28.4% 89
ABBV ABBVIE INC. $505.6B 48.7 +10.7% +23.3% 49
MRK Merck & Co., Inc. $339.7B 136.2 +4.9% +24.1% 56
NVS Novartis AG $293.1B — — +9.0% 30
AZN AstraZeneca PLC $277.2B — — +90.8% 20
ABT Abbott Laboratories $181.0B 38.5 +10.0% −16.3% 30
NVO Novo-Nordisk A/S $173.8B — — −25.9% 26
DAWN Day One Biopharmaceuticals, Inc. Common $2.2B — +20.6% +143.3% —
Peer median $316.4B 43.9 +10.0% +23.7% 34

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.58M
SI % of Float
8.61%
Days to Cover
5.39
Short Vol Ratio
34.3%
Free Float
76.45M
Float %
74.5%
Short interest 2026-04-15 • Short volume 2026-04-22 • Float 2026-02-17